Genentech Announcement : The FDA Approval Of Tamiflu For The Treatment Of Influenza In Infants
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has extended the approval of Tamiflu® (oseltamivir phosphate) for the treatment of acute, uncomplicated influenza to include infants two weeks of age and older.i Tamiflu is prescribed by doctors to help lessen the duration and severity of influenza by blocking the virus’ ability to replicate in the body.
